Loading, Please Wait...
PALO ALTO, Calif., April 08, 2019 (GLOBE NEWSWIRE) -- Auransa Inc., an artificial intelligence (AI)-driven biotechnology company developing precision medicines in areas of significant unmet medical need, today announced that the company will participate in BioCentury’s 26th Annual Future Leaders in the Biotech Industry Conference. Pek Lum, Ph.D., Auransa’s chief executive officer, will deliver a corporate presentation and participate in a panel discussion at the conference, which is being held April 12, 2019 at the Millennium Broadway Hotel & Conference Center in New York City.
Details for Auransa’s corporate presentation are as follows:
Dr. Lum will also participate in a panel discussion entitled, “Redefining Disease & Expanding the Druggable Universe.” Panelists will discuss how they are combining biological insights, novel technologies and digital science to redefine disease and address disease targets that had previously been considered beyond the reach of therapeutic intervention. Specifically, Dr. Lum will highlight Auransa’s artificial intelligence (AI)-driven SMarTR™ Engine, which leverages machine learning, advanced analytics and mathematics in an AI framework to generate insights from molecular data for a deep understanding of disease biology and patient subtypes. To date, Auransa’s SMarTR Engine has successfully generated a broad pipeline of drug candidates that are advancing toward investigational new drug (IND) filings.
Details for Auransa’s panel participation are as follows:
Additionally, the Auransa management team will take part in 1-on-1 meetings at the conference. To request a meeting with Auransa at BioCentury’s Future Leaders conference, please contact Stephanie Diaz of Vida Strategic Partners at email@example.com.
Founded in 2014, Auransa is an artificial intelligence (AI)-driven biotechnology company developing precision medicines in areas of significant unmet medical need. The company is working to redefine precision medicine by combining a sophisticated, proprietary predictive computational platform with traditional pharmaceutical industry experience. The company’s SMarTR™ Engine, which leverages machine learning, advanced analytics and mathematics in an AI framework, generates insights from molecular data for a deep understanding of disease biology and patient subtypes. This information, when paired with the company’s breadth of in-house drug discovery and development expertise, drives the identification of novel compounds designed to most effectively address significant unmet medical needs for clinically meaningful disease subtypes. The company has successfully generated a broad pipeline of drug candidates that are advancing toward investigational new drug (IND) filings. While Auransa is internally focused on oncology, the SMarTR Engine has also generated candidates in the areas of neurology, inflammation, infectious disease and metabolic disease. In addition to the programs being advanced internally, Auransa has also entered into an exclusive regional licensing agreement with a subsidiary of Lee’s Pharmaceutical Holdings Ltd. for the development and commercialization of one of the first programs generated by the SMarTR Engine. For more information, please visit: www.auransa.com.
Contacts: For Auransa: Vida Strategic Partners Stephanie Diaz (investors) 415-675-7401 firstname.lastname@example.org Tim Brons (media) 415-675-7402 email@example.com